EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer

Su-Jin Choi, Jii Bum Lee iD, Jae Hwan Kim, Min Hee Hong, Byoung Chul Cho iD, Sun Min Lim iD

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241240657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 21.03.2024. Verfasst von Su-Jin Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: national research foundation of korea, ministry of science and ict, south korea, JBL.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small-cell lung cancer (NSCLC). However, the role of CGP remains elusive in resectable NSCLC. Here, we elucidate the feasibility of CGP in early-stage NSCLC Korean patients and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.

Methods

All surgically resected NSCLC samples ( N = 96) were analyzed to assess the concordance in TMB calculation and targetable mutations using whole-exome sequencing (WES) and TruSight Oncology 500 (TSO500). In all, 26 samples were analyzed with Foundation One CDx Assay (F1CDx). Programmed death-ligand 1 (PD-L1) expression was evaluated using Vectra Polaris.

Results

Stage distribution post-surgery was 80% I ( N = 77) and 20% II ( N = 19). Ninety-nine percent ( N = 95) were adenocarcinoma. The median TMB with WES and TSO500 was 1.6 and 4.7 mut/Mb, respectively ( p < 0.05). Using all three platforms, the median TMB was 1.9, 5.5, and 4 mut/Mb for WES, TSO500, and F1CDx, respectively ( p = 0.0048). Linear regression analysis of TMB values calculated between WES and TSO500 resulted in a concordance correlation coefficient of 0.83. For the PD-L1 tumor proportion score of

Schlagwörter

Stichwörter der Autor:innen

PD-L1comprehensive genomic profilingearly stagenon-small-cell lung cancertumor mutation burden

Autor:innen und Institutionen

  • Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
  • Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, South Korea.

ORCID-Profile: Jii Bum Lee, Byoung Chul Cho, Sun Min Lim

Förderung

  • national research foundation of korea
  • ministry of science and ict, south korea
  • JBL
  • SML

Zitieren

APA

Choi, S. J., Lee, J. B., Kim, J. H., Hong, M. H., Cho, B. C., & Lim, S. M. (2024). Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241240657

Vancouver

Choi SJ, Lee JB, Kim JH, Hong MH, Cho BC, Lim SM. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241240657

BibTeX
@article{Choi2024,
  author = {Choi, Su-Jin and Lee, Jii Bum and Kim, Jae Hwan and Hong, Min Hee and Cho, Byoung Chul and Lim, Sun Min},
  title = {Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241240657}
}
Kostenlos starten →